How Chronic Kidney Disease Progresses Through Five Stages

37 Million Americans With Damage They Cannot Feel

Chronic kidney disease (CKD) affects approximately 37 million adults in the United States, roughly 15 percent of the adult population. Yet 9 out of 10 people with CKD do not know they have it, according to the CDC. The kidneys lose function gradually, often over years or decades, without producing symptoms until significant damage has accumulated. By the time patients notice changes, they may already be in an advanced stage.

CKD ranks as the eighth leading cause of death in the United States. Diabetes and hypertension account for nearly 75 percent of new cases. The disease follows a predictable trajectory through five stages, classified by glomerular filtration rate (GFR), the volume of blood the kidneys filter per minute.

The Five Stages: From Silent Damage to Kidney Failure

The KDIGO (Kidney Disease: Improving Global Outcomes) framework classifies CKD using both GFR and albuminuria levels. Each stage carries different implications for management and prognosis.

Kidney damage markers include persistent albuminuria (albumin-to-creatinine ratio above 30 mg/g), abnormal urine sediment, structural abnormalities on imaging, or a history of kidney transplantation. A patient with a GFR of 95 but persistent albuminuria has Stage 1 CKD.

Why the Kidneys Deteriorate: A Cycle of Scarring

Healthy kidneys contain roughly one million nephrons each. These microscopic filtering units process about 180 liters of blood daily. When nephrons are damaged by diabetes, hypertension, or other insults, the surviving nephrons compensate by increasing their individual filtration rate. This hyperfiltration sustains overall kidney function temporarily but accelerates further nephron loss. A vicious cycle begins.

Damaged glomeruli leak protein into the urine. Proteinuria itself is toxic to the tubular cells downstream, triggering inflammation and fibrosis. As scar tissue replaces functional kidney tissue, GFR declines further. Risk factors that accelerate this progression include:

• Uncontrolled diabetes (HbA1c above 7%)
• Uncontrolled hypertension (blood pressure above 130/80 mmHg)
• Heavy proteinuria (albumin-to-creatinine ratio above 300 mg/g)
• Smoking, which reduces renal blood flow
• Acute kidney injury episodes, each of which damages nephrons permanently
• Nephrotoxic medications including NSAIDs and certain antibiotics
• Obesity and metabolic syndrome

Complications That Accumulate With Each Stage

As kidney function declines, the organs can no longer perform their diverse roles: filtering waste, regulating blood pressure, producing erythropoietin, activating vitamin D, and maintaining electrolyte balance. Complications stack up progressively.

Anemia develops as the kidneys produce less erythropoietin, the hormone that stimulates red blood cell production. It typically appears around Stage 3b. Mineral and bone disorder (CKD-MBD) follows from impaired phosphate excretion and decreased active vitamin D synthesis, leading to secondary hyperparathyroidism, bone weakening, and vascular calcification.

Cardiovascular disease is the leading cause of death in CKD patients at every stage. A patient with Stage 3 CKD is far more likely to die of a heart attack than to reach dialysis.

Slowing the Decline: Evidence-Based Interventions

Blood pressure control is the single most impactful intervention. ACE inhibitors and angiotensin receptor blockers (ARBs) reduce proteinuria and slow GFR decline. Target blood pressure in CKD with significant proteinuria is below 130/80 mmHg. SGLT2 inhibitors, originally developed for diabetes, have emerged as game-changers. The DAPA-CKD trial showed dapagliflozin reduced the risk of kidney failure by 39 percent in CKD patients regardless of diabetes status.

• ACE inhibitors or ARBs: first-line for proteinuric CKD
• SGLT2 inhibitors: dapagliflozin and empagliflozin, effective in diabetic and non-diabetic CKD
• Finerenone: non-steroidal mineralocorticoid receptor antagonist, reduces kidney and cardiovascular events in diabetic CKD
• Glycemic control: HbA1c target of less than 7% for most diabetic CKD patients
• Dietary sodium restriction: below 2,300 mg daily
• Avoiding nephrotoxins: NSAIDs, iodinated contrast when possible

When Kidneys Fail: Dialysis and Transplantation

Stage 5 CKD, or end-stage kidney disease (ESKD), requires renal replacement therapy. About 550,000 Americans receive dialysis and roughly 250,000 live with a functioning kidney transplant. Hemodialysis filters blood through an external machine, typically three times per week for four hours. Peritoneal dialysis uses the abdominal lining as a filter, offering more flexibility but requiring daily exchanges.

Kidney transplantation offers the best long-term survival and quality of life. A transplant from a living donor can last 15 to 20 years; a deceased donor kidney averages 10 to 15 years. The waitlist in the United States exceeds 90,000 people, with a median wait time of 3 to 5 years. Early referral to nephrology, ideally at Stage 3b or earlier, improves preparation for renal replacement therapy and overall outcomes. This article is for informational purposes only. Consult a qualified professional.